489 An early phase expansion cohort study of fianlimab (anti–lymphocyte activation gene-3 [LAG-3]) plus cemiplimab (anti–programmed cell death-1 [PD-1]) in patients with advanced malignancies

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Regular and Young Investigator Award Abstracts

Topics

Biology

Cancer Oncology

Chemistry

Medicine

Internal Medicine

Show all topics

DOI

10.1136/jitc-2024-sitc2024.0489

License

CC-BY-NC

Other Formats

PDF